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Background: Rare chronic diseases of childhood are often complex and associated with multiple health issues.
Such conditions present significant demands on health services, but the degree of these demands is seldom
reported. This study details the utilisation of hospital services and associated costs in a single case of surfactant
protein C deficiency, an example of childhood interstitial lung disease.
Methods: Hospital records and case notes for a single patient were reviewed. Costs associated with inpatient
services were extracted from a paediatric hospital database. Actual costs were compared to cost estimates based
on both disease/procedure-related cost averages for inpatient hospital episodes and a recently implemented
Australian hospital funding algorithm (activity-based funding).
Results: To age 8 years and 10 months the child was a hospital inpatient for 443 days over 32 admissions. A total
of 298 days were spent in paediatric intensive care. Investigations included 58 chest x-rays, 9 bronchoscopies, 10
lung function tests and 11 sleep studies. Comprehensive disease management failed to prevent respiratory decline
and a lung transplant was required. Costs of inpatient care at three tertiary hospitals totalled $966,531 (Australian
dollars). Disease- and procedure-related cost averages underestimated costs of paediatric inpatient services for this
patient by 68%. An activity-based funding algorithm that is currently being adopted in Australia estimated the cost
of hospital health service provision with more accuracy.
Conclusions: Health service usage and inpatient costs for this case of rare chronic childhood respiratory disease
were substantial. This case study demonstrates that disease- and procedure-related cost averages are insufficient to
estimate costs associated with rare chronic diseases that require complex management. This indicates that the
health service use for similar episodes of hospital care is greater for children with rare diseases than other children.
The impacts of rare chronic childhood diseases should be considered when planning resources for paediatric health
services.
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Chronic disease in children occurs in the context of
rapid physical and mental development, necessitating
more complex care than in adults [1]. Medical manage-
ment and treatment planning must take into consider-
ation implications for long-term health and well-being
during childhood, adolescence and into adulthood.
Of the 37% of children in Australia living with a chronic
disease, 10% are affected by asthma and the rest are af-
fected by a diverse range of conditions [2], many of which
are rare (defined by the European Union as affecting less
than 5 persons per 10,000 of the population) [3]. Children
with rare chronic conditions often require care by multiple
paediatric specialists and allied health professionals,
necessitating effective coordination of services and service
providers.
Rare diseases of childhood present demands on health
services and families [4]. A lack of clinical guidelines for
many rare conditions, coupled with limited experience
and expertise among health professionals in the broader
community contribute to the increased burden on services
[5]. The burden of rare chronic paediatric disease on
families, the health system and the economy is likely to be
substantial, however empirical evidence for this is lacking.
Childhood interstitial lung disease (ChILD) is a hetero-
geneous group of rare childhood respiratory diseases
[6,7]. ChILD conditions affect the lung interstitium (the
tissue and space around alveoli where gas exchange
occurs) and have a different aetiology to that of adults
with interstitial lung disease [8]. ChILD associated with
an autosomal dominant mutationa in the surfactant pro-
tein C (SP-C) gene was first described in 2001 [9]. SP-C
has a role in surfactant function to reduce surface ten-
sion and prevent atelectasis [10]. SP-C may also have
anti-inflammatory properties [11]. Disease severity asso-
ciated with SP-C deficiency is highly variable, ranging
from asymptomatic to severe respiratory distress and de-
teriorating lung function that is exacerbated by recurring
viral and bacterial lung infections [12-17]. The variable
natural history of the disease and absence of rando-
mised, placebo-controlled trials or cross-over studies
means that optimal therapies for individuals with SP-C
deficiency are unknown [15]. Treatment is supportive
with nutrition and, oxygen and/or non-invasive ventila-
tion. Drug treatment is focussed on improving lung
function through reducing lower airway inflammation
with corticosteroids, hydroxychloroquine and azithromy-
cin [16,18,19]. In some cases of severe respiratory failure,
lung transplant is the only treatment option [17,20].
Here we describe the health services utilisation and asso-
ciated financial costs of care of a child with a severe case
of chronic ChILD due to SP-C deficiency.
In Australia, costs associated with public hospital-
based care are generally covered by the governmentthrough Medicare [21]. This includes all non-elective
surgery and treatments conducted at tertiary and paedi-
atric hospitals. Hospitals are funded by the government
according to the number and type (casemix) of patients
that they treat [22]. Central to this system of budgeting
hospital costs is classifying each inpatient episode by
diagnosis and/or procedure (Australian Refined Diag-
nosis Related Group (AR-DRG)) [23]. As part of the
National Health Reform Agreement 2011 [24] between
the Australian Federal Government and individual State
Governments, AR-DRG are to be applied to a complex
algorithm so that each episode of hospital care is quan-
tified and normalised to a National Weighted Activity
Unit (NWAU). The number of NWAUs for each hos-
pital episode is multiplied by a National Efficient Price
to determine the estimated cost associated with each
episode of care. The National Efficient Price is deter-
mined annually by a body that is independent of gov-
ernment, the Independent Hospital Pricing Authority
(IHPA) [25]. This funding arrangement is called “activ-
ity-based funding”. Activity-based funding is being pro-
gressively implemented in Australia from 2012 and is
designed to standardise the measurement of resource
requirements of hospitals across demographics, geog-
raphies and medical specialties.
In this study we have applied activity-based funding
calculations to the tertiary, paediatric inpatient episodes
of this single patient with ChILD. We compared the ac-
tual costs of paediatric inpatient episodes with activity-
based funding estimates and with AR-DRG-related cost
averages.Methods
Health service utilisation data were obtained from a de-
tailed review of the patient’s case notes, hospital records
and information provided by managing physicians.
Costs of care were examined for inpatient tertiary hos-
pital episodes only. Actual costs of hospital services were
extracted from databases of the Management Support
and Analysis Unit, Sydney Children’s Hospitals Network
(SCHN)-which comprises of two paediatric hospitals in
Sydney, Australia (The Children’s Hospital at Westmead
and Sydney Children’s Hospital, Randwick) and Health
Information Services, Alfred Health, Melbourne, Australia.
Budget estimates of services provided by the SCHN were
determined from AR-DRG-associated cost averages for in-
patient episodes. AR-DRG’s were assigned by medical
coders in hospital Medical Records Departments. Activity-
based funding estimates for inpatient health services pro-
vided by the SCHN were determined by entering data for
each hospital episode for this case into the IHPA 2012–13,
NWAU calculator [26].
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collection and publication of de-identified information
relating to the health service use and medical needs of
the child. Approval was also obtained from the Research
Ethics Committee of the SCHN to conduct this study.
Analysis
Summed number of presentations to Emergency Depart-
ments, hospital admissions, inpatient days in hospital,
inpatient days in the paediatric intensive care unit (PICU),
outpatient consults and common clinical investigations are
described. An admission is defined as a stay in hospital of
four hours or more. Hospital services usage is described
until the patient was aged 8 years, 10 months. Whereas
costs of tertiary hospital inpatient services (SCHN hospitals
and a paediatric transplant unit in an adult hospital where
the lung transplant was performed) are described until the
child was aged 7 years, 9 months.
Results
Clinical course and health service use
Following a clomiphene assisted conception, an unevent-
ful pregnancy and delivery of a female infant ensued.
The infant was initially admitted to a small regional hos-
pital outside of Sydney at 21 days of age for failure to
thrive. Over four days the infant gained weight and was
discharged home but returned to hospital in the evening
of the day of discharge with respiratory distress. The
infant was transferred 164 kilometres by emergency
transport to The Children’s Hospital at Westmead in
Sydney, a tertiary/quaternary paediatric hospital. The
infant remained in this hospital during the next few
months, where multiple investigations (bronchoscopy,
thoracoscopic lung biopsy, computed axial tomography
of the chest and chest x-rays) were performed and a
provisional diagnosis of chronic pneumonitis of infancy
(a type of ChILD) was determined. A lung biopsy sample
was sent to a histopathologist in the USA who specialised
in ChILD. Their analysis supported the diagnosis of
chronic pneumonitis of infancy and, immunohisto-
chemistry performed by this specialist suggested a sur-
factant protein deficiency. A mutation in the SP-C
gene was confirmed when the infant was 5 months old
by genetic test in the USA. Respiratory symptoms were
treated with corticosteroids, hydroxychloroquine and
continuous oxygen. With continuous nasogastric feeds
the infant gained weight and at 3 months of age she was
transferred back to the regional hospital for a further
month until discharge home on continuous oxygen
therapy.
At 7 months of age the infant was admitted to PICU
with respiratory failure and severe nocturnal hypoxic
episodes, discovered during a scheduled sleep study.
Bi-level positive airway pressure (BiPAP) non-invasiveventilation was commenced. Gastro-oesophageal reflux
and poor feeding required laparoscopic fundoplication
and gastrostomy. A chest infection required intubation.
At 14 months of age the infant was discharged on con-
tinuous oxygen therapy, nocturnal BiPAP and support
from a community health care team (case manager,
nurse, general paediatrician) was arranged.
Respiratory function slowly and progressively declined
despite pharmacotherapy, oxygen and BiPAP. Pancreatic
insufficiency causing chronic fatty diarrhoea (not known
to be associated with ChILD) responded to regular
pancreatic enzyme replacement therapy. A sweat test
excluded cystic fibrosis as the cause of the pancreatic
insufficiency. The respiratory deterioration accelerated
following a respiratory syncytial virus infection at
4 years of age that required an emergency transfer from
the regional hospital to Sydney Children’s Hospital and a
14 day stay in PICU. At 6 years of age the child had end
stage respiratory failure and pulmonary artery hyperten-
sion, and was wheelchair bound. She continued to have an
aversion to oral feeds and was gastrostomy fed. Proximal
muscle weakness and mild developmental delay required
physiotherapy and speech therapy. She had mid-face
hypoplasia, partly attributed to the use of non-invasive
face mask ventilation from late infancy.
At age 6 years and 10 months the child underwent
a bilateral, sequential lung transplant in a paediatric
transplant unit in an adult tertiary/quaternary hospital
(The Alfred Hospital, Melbourne, Australia). Four months
post-transplant the child no longer required respiratory
support and nine months post-transplant she could exer-
cise without limitation. Post-operative medical issues that
were resolved included: tachycardia, atrial arrhythmia,
thrombosis, vocal cord palsy and stenotrophomonas
maltophilia colonisation of the airways.
Ongoing medical issues at 8 years and 10 months of
age were: aversion to oral feeds, leakage of feeds from
the gastrostomy site, complications from chronic use of
corticosteroids (glucose intolerance, osteoporosis and
hypertrichosis), mid-face hypoplasia and malocclusion
(related to the long term use of non-invasive face mask
ventilation), speech and language delay, lifelong im-
munosuppression for Epstein-Barr Virus mismatched
donor lungs, medication-related leukopenia, bronchial
anastomosis stenosis requiring repeated dilatation by
bronchoscopy, pseudomonas colonisation of the lungs and
intermittent morning nausea.Use of hospital services
The child had 32 hospital admissions and spent more than
one year (443 days) of her first 8 years and 10 months of
life in hospital for management of ChILD and associated
respiratory infections, including 298 days in PICU
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spent as a hospital inpatient.
Three lengthy hospital stays accounted for the ma-
jority of inpatient service use and occurred mainly
during the first 2 years of life (Figure 1). Firstly, a
period of 126 days in the first few months of life to sta-
bilise respiratory function and, to determine a preliminary
diagnosis and management plan. Two direct transfers
between the regional hospital and paediatric hospital in
Sydney (The Children’s Hospital at Westmead) occurredTable 1 Hospital admissions, presentations to emergency
departments and outpatient clinic attendances
Admissions
Tertiary hospital admissions
Paediatric hospital managing the condition of ChILD 22
Other paediatric hospital 1
Adult hospital with paediatric lung transplant unit 4
Regional hospital admissions 5
Total 32
Reasons for hospital admissions
Respiratory distress 7





Respiratory airway dilation (post-lung transplant) 5
Lung transplant 1
Sleep study (scheduled) 1
Inpatient days
Days as an inpatient of tertiary hospitals
Paediatric hospital managing the condition of ChILD 337
Other paediatric hospital 14
Adult hospital with paediatric lung transplant unit 33
Days as an inpatient of the regional hospital 61
Total* 443
Total number of days in PICUa 298
Presentations to Emergency Departments 10
Direct transfers between regional and tertiary hospitals 3
Outpatient attendances**
Tertiary hospital clinics 18
Regional hospital clinics 9
Total 27
*The total is less than the sum of tertiary and regional hospital inpatient days
because on two occasions the patient was an inpatient of two hospitals on
the same day.
**Does not include outpatient clinic consults while the patient was
an inpatient.
aPICU, Paediatric Intensive Care Unit.during this time. Secondly, there was a 199 day admission
to manage a critical deterioration of respiratory function
before the child’s first birthday. Thirdly, in her seventh
year the child spent 30 days in hospital for a lung trans-
plant. Among the total of 32 hospital admissions, seven
were for respiratory distress, two related to acute respira-
tory infections and all other admissions were for investiga-
tions or procedures associated with the management of
ChILD (Table 1). In addition, there were 27 consults at
hospital outpatient clinics.
Intensive, ongoing treatment (pharmacotherapy, oxy-
gen and BiPAP) coincided with a reduction in the use of
hospital services between the ages of 2 and 4 years.
From 4 years of age respiratory function declined, result-
ing in an increase in the use of inpatient services. The
lung transplant at age 6 years and 10 months along with
post-operative monitoring and treatment accounted for
a further increase in hospital services use. At age 8 years
the child’s condition was considerably improved and
whilst hospital service use had decreased she continues
to be seen every two to three months for ongoing post-
lung transplant care.
At least 30 different health professionals were involved
in the hospital-based care and disease management
(Table 2). Experts in the USA, UK and Germany were
also consulted.
Numerous investigations were conducted at The Chil-
dren’s Hospital at Westmead including a total of 58 chest
x-rays for diagnosis, disease monitoring and to guide clin-
ical procedures. Two lung biopsies were performed for
diagnostic purposes. Bronchoscopies (total = 9) were per-
formed to monitor for signs of donor lung rejection
(transbronchial biopsy) or lung infection (bronchoalveolar
lavage) or, to dilate the bronchial anastomotic stenosis that
had developed post-lung transplantation. Lung function
tests (total = 10) and sleep studies (total = 11) were regu-
larly performed pre-lung transplant to monitor disease
progression. Many investigations were not scheduled prior
to admission but performed as a component of disease
management during a hospital stay. For example only one
of the 11 sleep studies was scheduled prior to admission.
In addition to the lung transplant, surgical procedures
included gastrostomy and laparoscopic fundoplication.
Seventeen different medications prescribed for the
treatment of ChILD, complications of ChILD and other
medical issues arising from treatment were needed either
continuously or intermittently over several years. The medi-
cations included: hydroxychloroquine, corticosteroids and
anti-cholinergics to treat respiratory symptoms; antibiotics
and antivirals to treat respiratory infections; immunosup-
pressants to prevent rejection of the transplanted lungs.
Medications were also required to treat pancreatic in-














Figure 1 Timeline of hospital service use for a single patient with ChILDa. Shown on the timeline are all hospital admissions and attendances
at hospital outpatient clinics including: tertiary paediatric hospitals, a tertiary adult hospital (for a lung transplant) and a small, regional hospital. The
length of stay for each hospital admission is represented by the width of the shaded block. Attendances at hospital outpatient clinics do not include
consults at outpatient clinics while the patient was an inpatient. The unit of the time line is the patient’s age in years. aChILD, childhood interstitial
lung disease.
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tinuous home oxygen therapy and nocturnal BiPAP
ventilation for more than 2,000 days. Oxygen cylinders
were regularly supplied via the regional hospital. A State
Government service (EnableNSW) provided the family
with two BiPAP ventilators and paid for the home oxygen.
The Children’s Hospital at Westmead provided manufac-
turing and fabrication support for medical equipment
from time to time.
Inpatient tertiary hospital service costs
The total cost of inpatient services provided by tertiary
hospitals (paediatric and adult) until the patient was aged
7 years and 9 months was $966,531 (Australian dollars),Table 2 Hospital-based disciplines involved in the









Nurse practitioner Transplant nurse
Respiratory technician Dermatologist
Clinical nurse consultant Pharmacist





Anaesthetist Geneticist (including USA*)
Surgeon Histopathologist
(including USA*)
*Expertise was utilised from physicians, geneticists and histopathologists in
the USA, UK and Germany.including $900,201 for paediatric hospitals (Table 3). An
estimate of paediatric inpatient service costs based on
AR-DRG-associated cost averages (budget estimate) was
only $284,297, underestimating the actual costs by 68%.
Activity-based funding estimates for inpatient services
at the paediatric hospitals, based on the National Effi-
cient Price 2012–13, totalled $1,201,996. This overesti-
mate of $301,795 on the actual costs is likely due to
the application of the current National Efficient Price
(2012–13) to hospital encounters for the previous eight
years, when service costs were lower.
Discussion
This case study demonstrates the frequent use of tertiary
paediatric inpatient services, secondary general inpatient
services and, outpatient services associated with the
management of a rare chronic lung disease. The tertiary
paediatric inpatient service costs of disease management
were extremely high at AU$ 900,201 over eight years for
this one case.
The child in this case study spent 443 days as a hospital
inpatient during 32 admissions in her first 8 years and
10 months of life, an average of 50 days as an inpatient per
year. In Australia in 2011–12 the total number of inpatient
days for children aged 0–9 years was approximately
1,475,000 [27], amounting to an average of 0.5 patient-
days per child per year based on a population of 2,908,425
children (0–9 years) [28]. Thus the inpatient health service
requirements for the child in this study are one hundred
times greater than the needs of an average Australian
child.
Over 30 different health professionals were involved in
the child’s care. A significant proportion of the health
service cost occurred in the first two years, when a man-
agement strategy was being devised for a rare disease for
which clinical guidelines were not available. The patient
developed an aversion to oral feeding as a result of poor
lung function and this required a gastrostomy and its
Table 3 Costs of tertiary hospital inpatient services until the patient was aged 7 years and 9 months (11 months
post-lung transplant)
Service provider Actual costs Budget estimate Activity-based funding estimate
Australian dollars
Paediatric hospitals 900,201 284,297 1,201,996
Adult hospital 66,330
Total 966,531
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chloroquine required ophthalmologic monitoring for
macular toxicity; chronic use of non-invasive ventilation
resulted in mid-face hypoplasia, impairing jaw and tooth
development and causing further problems with breath-
ing and speech. Management of these adjunct health
issues greatly contributed to the use and cost of health
services.
The chronicity and complexity of rare childhood con-
ditions requires management by many highly trained
specialists, a variety of specialist services and, other
health professionals thereby impacting on health re-
sources [4,29]. A number of reports have shown that
children with chronic and complex conditions contrib-
ute significantly to paediatric health service burdens
and costs [4,30,31]. Colvin and Bower reported that the
length of hospital stay is greater in children with com-
plex birth defects than other children, for hospital
admissions for the same diagnosis [30]. A retrospective
cohort analysis in 37 United States tertiary paediatric
hospitals found that patients with more than three
readmissions in one year accounted for only 2.9% of all
patients admitted, but 18.8% of all admissions and
23.2% of all hospital charges [31]. In a population-
based study in the United States of children with
chronic conditions, the 5% that were categorised as
severe accounted for 33% of all hospital admission days
resulting from chronic disease [32].
Estimated costs of paediatric inpatient services for this
patient, based on the AR-DRG-related cost averages
used in Australia prior to 2012, were 68% less than ac-
tual costs. This demonstrates the limitation of DRG clas-
sifications to estimate health service costs associated
with rare chronic and complex paediatric conditions.
The DRG classification system relies on accurate coding
assigned to each inpatient episode. This may be difficult
to achieve for rare diseases that do not easily fit into an
identifiable classification and where there are multiple
morbidities. Acute episodes of illness in children with
underlying chronic disease tend to be more complex
and severe and therefore more costly when compared
with the same acute care in children without underlying
chronic complex conditions [33]. In a previous analysis
of paediatric inpatient costs, the actual costs of specialist
expert care in paediatric tertiary/quaternary hospitalshas been underestimated by 77% when using the AR-DRG
casemix system due to the large number of comorbidities
and complications affecting admitted children [34]. This
is similar to the 68% underestimate based on AR-DRG-
related cost averages estimated for our single case.
In Australia, the recently implemented activity-based
funding model of resource allocation uses an algorithm
that incorporates not only AR-DRG diagnostic/proced-
ural codes but also other variables such as hospital level
of specialty, length of stay, hours in intensive care and a
paediatric weighting [25]. Applying the activity-based
funding model in our case study overestimated costs by
33%. This was expected because historical data were
entered into the 2012–13 version of the model, which is
based on current costs. The activity-based funding model
appears to provide a closer approximation to actual in-
patient costs for our case than the AR-DRG-related cost
averages estimate.
Our study is limited to a description of a single, very
severe case requiring lung transplant that does not rep-
resent all children with rare chronic lung diseases. Other
rare, complex and chronic childhood diseases are likely
to have significant impacts through frequent use of mul-
tiple services and associated high costs [4]. We only ana-
lysed the direct costs of hospital admissions. Costs were
not analysed for: medications (chronic use of 17 medica-
tions), allied health services, pathology and imaging out-
side of the hospital system, admissions to a regional
hospital (61 inpatient days), outpatient consultations and
emergency transport (164 km between regional and paedi-
atric hospitals). These additional costs are likely to be sub-
stantial and would have impacted on the Australian health
care system. Furthermore, out-of-pocket health and non-
health costs to the family have not been accounted for.
Cost savings may be possible when dealing with com-
plex and chronic conditions through treatment discovery,
development and implementation of evidence-based
clinical guidelines, coordination and integration of mul-
tiple health services, and education of health professionals
[35-37]. High quality research evidence and clinical trials
are needed to support such developments.
Conclusion
The case described here, and other literature, suggests
that although rare chronic conditions may be few in
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and that these costs are likely to be underestimated.
This needs to be taken into account when planning and
funding health services. The new Australian system of
resource allocation (activity-based funding) is likely to
more accurately estimate costs associated with rare com-
plex chronic childhood diseases than disease or procedure
associated cost averages. Further evidence on large groups
of diverse rare diseases is needed to support appropriate
resourcing of health services to cover the real costs of rare
chronic diseases to the health system. We are currently
undertaking a large study funded by the Australian
Research Council (Grant LP 110200277) to address this
gap in knowledge.Endnote
aMutations in the SP-C gene can also arise de novo
and this was the case for the mutation in this case study
as neither parent had the mutation.
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